Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) has earned an average recommendation of “Moderate Buy” from the nine brokerages that are presently covering the firm, Marketbeat.com reports. Six research analysts have rated the stock with a hold recommendation, one has assigned a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $32.00.

CPRX has been the topic of several recent analyst reports. Robert W. Baird lowered Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 7th. Wall Street Zen lowered Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Citigroup lowered Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $35.00 to $31.50 in a research note on Friday, May 8th. HC Wainwright cut Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their target price for the company from $35.00 to $31.50 in a research report on Thursday, May 28th. Finally, Oppenheimer downgraded Catalyst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 7th.

Hedge Funds Weigh In On Catalyst Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. Advisory Services Network LLC acquired a new stake in Catalyst Pharmaceuticals in the third quarter valued at approximately $39,000. Quarry LP bought a new stake in shares of Catalyst Pharmaceuticals during the third quarter worth $40,000. Clearstead Advisors LLC increased its holdings in shares of Catalyst Pharmaceuticals by 192.9% during the fourth quarter. Clearstead Advisors LLC now owns 1,772 shares of the biopharmaceutical company’s stock worth $41,000 after buying an additional 1,167 shares in the last quarter. Smartleaf Asset Management LLC increased its holdings in shares of Catalyst Pharmaceuticals by 55.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,764 shares of the biopharmaceutical company’s stock worth $41,000 after buying an additional 630 shares in the last quarter. Finally, Larson Financial Group LLC lifted its stake in shares of Catalyst Pharmaceuticals by 552.7% in the 4th quarter. Larson Financial Group LLC now owns 1,847 shares of the biopharmaceutical company’s stock valued at $43,000 after acquiring an additional 1,564 shares during the last quarter. 79.22% of the stock is currently owned by institutional investors and hedge funds.

Catalyst Pharmaceuticals Price Performance

NASDAQ CPRX opened at $31.49 on Thursday. The business has a fifty day moving average price of $31.40 and a two-hundred day moving average price of $27.51. Catalyst Pharmaceuticals has a fifty-two week low of $19.05 and a fifty-two week high of $32.56. The stock has a market capitalization of $3.86 billion, a PE ratio of 18.10, a PEG ratio of 0.96 and a beta of 0.74.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).